跳到正文
Drug Discovery & Development· Brian Buntz·· 28 天前AI 评分66

罗氏选定癌症靶点,翰森制药负责ADC开发,交易预付款4亿美元

Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront

AI 导读

罗氏与翰森制药达成新的ADC合作,罗氏支付4亿美元预付款并提出癌症靶点,翰森制药利用其ADC平台开发候选疗法。协议涵盖翰森制药两个已有临床前项目,并新增针对罗氏提出靶点的项目,翰森制药将推进至全球Phase Ia,之后由罗氏负责中国大陆、香港、澳门和台湾以外地区的后续开发。翰森制药还将在协议一周年获得1.1亿美元,并有资格获得超过150亿美元里程碑付款及销售分成。

正文 · 原文

Roche Towers, Basel, Switzerland

Roche Towers in Basel, Switzerland. [Adobe Stock]

Roche is expanding a string of deals with Chinese drugmakers, committing $400 million upfront to a Hansoh Pharma partnership that will help build its future cancer pipeline. Under an agreement announced Monday, Roche will propose cancer targets and Hansoh will use its antibody-drug conjugate platform to develop therapies against them.

The agreement expands a relationship that began last October, when Roche licensed Hansoh’s CDH17-targeting ADC HS-20110 for $80 million upfront. This time, Roche is securing access to two existing preclinical Hansoh programs and commissioning additional candidates against targets it proposes. Hansoh will engineer those therapies and take them into early human testing.

Roche used a similar approach in August, when its Genentech subsidiary agreed to pay DualityBio $45 million upfront to develop ADCs against Genentech-selected targets. DualityBio will lead discovery and early global clinical development, with Genentech taking over after Phase Ia. The Hansoh agreement extends that approach with a substantially larger upfront commitment, giving Roche another Chinese partner to translate its target choices into experimental cancer drugs.

Several agreements give Chinese partners responsibility for creating new candidates and advancing them through early trials, including programs proposed by the multinational buyer.

Selected Chinese drug licensing and discovery partnerships, 2025–2026
Global pharma / Chinese partner Announced What the agreement covers Development responsibilities Upfront / near-term payments
Roche and Genentech partnerships
Roche / Hansoh Oct. 2025 Existing CDH17-targeting ADC, HS-20110 Roche advances licensed candidate outside Hansoh’s retained territories $80 million
Genentech (Roche) / DualityBio Aug. 2026 New ADCs against Genentech-selected targets using DualityBio’s DUPAC payloads Discovery through global Phase Ia $45 million
Roche / Defand Oct. 2026 Molecular glue drugs for cancer and immune diseases Discovery and development of multiple new drugs Undisclosed
Roche / Rona Oct. 2026 ALK7-targeting RNAi obesity candidate, worldwide rights Existing candidate licensed Up to $100 million (upfront and near-term)
Roche / Hansoh Oct. 2026 Two preclinical ADCs plus new programs against Roche-proposed targets Development through global Phase Ia $400 million
Other pharma partnerships
AstraZeneca / CSPC Jan. 2026 Eight obesity and related disease programs, plus platform access Initial four through Phase I; development of four additional programs $1.2 billion
Bristol Myers Squibb / Hengrui May 2026 13 preclinical programs: four from Hengrui, four from BMS and five for joint discovery Leads early clinical development across the portfolio $600 million
Pfizer / Innovent May 2026 12 oncology programs (ADCs and multispecific antibodies): eight Innovent-originated, four Pfizer-proposed Development through Phase I; co-develops four programs globally $650 million
Eli Lilly / InnoCare Sept. 2026 Compounds against up to five undisclosed targets Discovery and early advancement; Lilly handles later development Up to $100 million (upfront and near-term)

Note: Selected agreements, not a comprehensive deal list. Amounts are in U.S. dollars and represent upfront payments unless otherwise indicated. Near-term payments may depend on specified conditions. Additional milestones and royalties vary by agreement. Program counts, territorial rights and development responsibilities also differ. Company names link to sources.

Under the latest agreement, Hansoh will lead development through global Phase Ia trials. Roche will then assume responsibility for further development outside mainland China, Hong Kong, Macau and Taiwan, where Hansoh retains rights. Alongside the $400 million upfront payment, Hansoh will receive $110 million on the agreement’s first anniversary and could earn more than $15 billion in development, regulatory and commercial milestones, plus royalties on future sales.

Hansoh also has the option to contribute to development of up to two programs outside its retained territories in exchange for additional commercial upside in the United States.

AstraZeneca has also turned to a Chinese partner to develop candidates through early human trials, signing a Jan. 30 agreement with CSPC Pharmaceutical covering eight programs for obesity and related diseases. The $1.2 billion upfront commitment includes access to CSPC’s peptide discovery and once-monthly dosing technologies. CSPC will take the initial four programs through Phase I while developing four additional programs, with AstraZeneca assuming later development and commercialization in its licensed territories following successful Phase I completion.

Big pharma now gets a significant share of its in-licensed drugs from China. According to DealForma data published by J.P. Morgan, Chinese assets accounted for 39% of global large-cap biopharma licensing deals with upfront payments of at least $50 million in 2025 through Dec. 15, and 32% of upfront payments within that group.


Filed Under: Drug Discovery, Oncology
Tagged With: antibody-drug conjugates (ADCs), AstraZeneca, biopharma licensing, cancer targets, CDH17, China biotech, CSPC Pharmaceutical, drug discovery, DualityBio, Genentech, Hansoh Pharma, HS-20110, milestone payments, oncology, Phase Ia trials, preclinical development, Roche, upfront payment


Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

来源:Drug Discovery & Development · drugdiscoverytrends.com